JAMA Pediatr:儿童等渗和低渗静脉注射之比较

2015-03-12 赵洲译 MedSci原创

在住院治疗的儿童中,低钠血症逐渐被视为是发病率和死亡率的原因。低渗静脉注射维持液体的规定概括了对液体和电解质要求。低渗静脉注射维持液体总体上维持了护理的标准。但是,人们逐渐意识到许多住院治疗的儿童分泌更多的抗利尿激素。此时低渗注射维持液体会导致医源性低钠血症。 研究人员进行了双盲随机试验以比较等渗(0.9%氯化钠和5%葡萄糖)和低渗(0.45%氯化钠和5%葡萄糖)对住院治疗的儿童的影响。共有11

在住院治疗的儿童中,低钠血症逐渐被视为是发病率和死亡率的原因。低渗静脉注射维持液体的规定概括了对液体和电解质要求。低渗静脉注射维持液体总体上维持了护理的标准。但是,人们逐渐意识到许多住院治疗的儿童分泌更多的抗利尿激素。此时低渗注射维持液体会导致医源性低钠血症。

研究人员进行了双盲随机试验以比较等渗(0.9%氯化钠和5%葡萄糖)和低渗(0.45%氯化钠和5%葡萄糖)对住院治疗的儿童的影响。共有110名儿童(年龄在1个月到18岁之间)参与此次随机试验。110名儿童随机接受等渗或者低渗注射维持液体48小时。试验的主要观测指标是48小时的平均血浆钠等级。次要指标是24小时的平均血钠等级、低钠血症和高钠血症、体重增加、高血压和水肿。110人中,54人接受等渗输液(0.9%氯化钠),56人接受低渗输液(0.45%氯化钠)。混杂变量被列入多元回归模型中。并没有因为此次试验而出现明显的不良反应。两组中各有一人因为呼吸困难而被转移至重症监护室,但这与静脉注射无关。

通过分析主要监测结果,研究人员并没有发现两种注射在临床上有着显著的差异。但在24小时的时候,低渗注射组出现了两例低钠血症。这一结果证明了等渗注射维持液体在儿童患者中是安全的。

原始出处:

Friedman JN, Beck CE, DeGroot J, Geary DF, Sklansky DJ, Freedman SB. Comparison of Isotonic and Hypotonic Intravenous Maintenance Fluids: A Randomized Clinical Trial. JAMA Pediatr. Published online March 09, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637055, encodeId=af33163e0550f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 19 19:44:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697242, encodeId=1a46169e24227, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Oct 23 11:44:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725777, encodeId=e2671e2577781, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 22 21:44:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18288, encodeId=d68f182883c, content=一般不都用等渗液体吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5dd21607321, createdName=daniustone, createdTime=Sat Mar 14 11:03:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492449, encodeId=18b31492449d6, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Mar 14 02:44:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18230, encodeId=7536182306d, content=最基本的输液还没有结论,可见临床上问题太多了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Fri Mar 13 10:20:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18159, encodeId=6c1618159fc, content=何时要用低渗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 16:27:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637055, encodeId=af33163e0550f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 19 19:44:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697242, encodeId=1a46169e24227, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Oct 23 11:44:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725777, encodeId=e2671e2577781, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 22 21:44:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18288, encodeId=d68f182883c, content=一般不都用等渗液体吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5dd21607321, createdName=daniustone, createdTime=Sat Mar 14 11:03:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492449, encodeId=18b31492449d6, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Mar 14 02:44:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18230, encodeId=7536182306d, content=最基本的输液还没有结论,可见临床上问题太多了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Fri Mar 13 10:20:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18159, encodeId=6c1618159fc, content=何时要用低渗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 16:27:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-10-23 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637055, encodeId=af33163e0550f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 19 19:44:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697242, encodeId=1a46169e24227, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Oct 23 11:44:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725777, encodeId=e2671e2577781, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 22 21:44:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18288, encodeId=d68f182883c, content=一般不都用等渗液体吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5dd21607321, createdName=daniustone, createdTime=Sat Mar 14 11:03:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492449, encodeId=18b31492449d6, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Mar 14 02:44:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18230, encodeId=7536182306d, content=最基本的输液还没有结论,可见临床上问题太多了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Fri Mar 13 10:20:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18159, encodeId=6c1618159fc, content=何时要用低渗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 16:27:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-07-22 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637055, encodeId=af33163e0550f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 19 19:44:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697242, encodeId=1a46169e24227, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Oct 23 11:44:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725777, encodeId=e2671e2577781, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 22 21:44:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18288, encodeId=d68f182883c, content=一般不都用等渗液体吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5dd21607321, createdName=daniustone, createdTime=Sat Mar 14 11:03:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492449, encodeId=18b31492449d6, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Mar 14 02:44:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18230, encodeId=7536182306d, content=最基本的输液还没有结论,可见临床上问题太多了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Fri Mar 13 10:20:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18159, encodeId=6c1618159fc, content=何时要用低渗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 16:27:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-03-14 daniustone

    一般不都用等渗液体吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1637055, encodeId=af33163e0550f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 19 19:44:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697242, encodeId=1a46169e24227, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Oct 23 11:44:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725777, encodeId=e2671e2577781, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 22 21:44:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18288, encodeId=d68f182883c, content=一般不都用等渗液体吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5dd21607321, createdName=daniustone, createdTime=Sat Mar 14 11:03:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492449, encodeId=18b31492449d6, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Mar 14 02:44:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18230, encodeId=7536182306d, content=最基本的输液还没有结论,可见临床上问题太多了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Fri Mar 13 10:20:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18159, encodeId=6c1618159fc, content=何时要用低渗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 16:27:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1637055, encodeId=af33163e0550f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 19 19:44:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697242, encodeId=1a46169e24227, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Oct 23 11:44:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725777, encodeId=e2671e2577781, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 22 21:44:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18288, encodeId=d68f182883c, content=一般不都用等渗液体吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5dd21607321, createdName=daniustone, createdTime=Sat Mar 14 11:03:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492449, encodeId=18b31492449d6, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Mar 14 02:44:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18230, encodeId=7536182306d, content=最基本的输液还没有结论,可见临床上问题太多了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Fri Mar 13 10:20:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18159, encodeId=6c1618159fc, content=何时要用低渗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 16:27:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-03-13 drhqh240

    最基本的输液还没有结论,可见临床上问题太多了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1637055, encodeId=af33163e0550f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Aug 19 19:44:00 CST 2015, time=2015-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697242, encodeId=1a46169e24227, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Oct 23 11:44:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725777, encodeId=e2671e2577781, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 22 21:44:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18288, encodeId=d68f182883c, content=一般不都用等渗液体吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5dd21607321, createdName=daniustone, createdTime=Sat Mar 14 11:03:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492449, encodeId=18b31492449d6, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Mar 14 02:44:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18230, encodeId=7536182306d, content=最基本的输液还没有结论,可见临床上问题太多了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=drhqh240, createdTime=Fri Mar 13 10:20:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18159, encodeId=6c1618159fc, content=何时要用低渗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 16:27:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-03-12 116.226.177.**

    何时要用低渗?

    0

相关资讯

MedPage:阿尔茨海默病药物静脉注射免疫球蛋白后期临床试验失败

静脉注射免疫球蛋白(IVIG)在备受关注的III期临床试验中未能阻止阿尔茨海默病的进展,又一个比较有前景的阿尔茨海默病药物的研发似乎要半途而废。根据临床试验主办单位百特国际提供的信息,在名为GAP(Gammaglobulin Alzheimer's Partnership)的安慰剂对照、周期为18个月的临床试验中,接受静脉注射免疫球蛋白治疗的受试者其认知或功能下降比率均没有明显差异,而这两项指标是

Neurology:麻醉药物治疗癫痫持续状态感染和死亡风险增高

目前对于癫痫持续状态的治疗,一般首选持续静脉给药,但关于麻醉药物治疗癫痫持续状态的风险和受益的研究并不多,为了更好的指导临床麻醉药物治疗癫痫持续状态,于是进行了本项研究。【原文下载】 针对这种情况,来自瑞士巴塞尔大学医院神经科的Raoul Sutter博士等人进行了一项研究,研究的目的是评估不断持续静脉注射麻醉药物(IVADs)对伴有癫痫持续状态(SE)成年患者结局的风险,其研究结果在线发表于